CytomX Therapeutics (CTMX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.09
- Estimate
- -$0.11
- Surprise
- +14.6%
- Revenue (period 2026-06-30)
- $1.4M
- Score today
- 3.8/10
Revenue source: xbrl.
How the report landed
CytomX Therapeutics (CTMX) reported a narrower loss than forecast — adjusted EPS of -$0.09 against the -$0.11 estimate (a 14.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CTMX Sell at 3.8/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +14.6% surprise compares with a -57.2% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: Varseta-M
- DATA_ISSUE: analyst_target_implausible (raw $12.25 vs price $2.41 — ratio 5.1×). Rejected, falling back to technical TP.
- Quality below floor (3.1 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $2.41
- Price target
- $2.94
- Stop
- $2.24
- Upside to target
- +22.0%
Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.
CTMX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $525.1M
- P/E (fwd)
- -5.1
- 52-week range
- $2.20–$8.21
- Off 52-week high
- 70.6%
- RSI (14)
- 36
- Volume vs avg
- 0.79×
- Score today
- 3.8/10